Literature DB >> 15010826

Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology.

Christian Melle1, Roland Kaufmann, Merten Hommann, Annett Bleul, Dominik Driesch, Günther Ernst, Ferdinand von Eggeling.   

Abstract

At present, the molecular mechanisms of hepatocellular carcinogenesis are not well understood. It is known, however, that cancer development and progression are accompanied by profound changes at the cellular and subcellular level, involving RNA/DNA and protein structure and function. Therefore, high-throughput, proteomic techniques targeting these biological molecules may provide novel insights into HCC genesis and prognosis. We characterized tissue protein profiles from 10 HCC patients using ProteinChip technology (SELDI) which is able to detect minute amounts of proteins and moreover to analyze complex protein pattern. Therefore, after histopathological examination, proteins from kryostat sections of non-tumorous hepatic tissue as well as from central and peripheral tumor areas were isolated from complete histological sections or from selected and microdissected tissue areas. Analysis on the SAX and WCX ProteinChip Arrays revealed 14-26, and 25-29 differentially expressed peaks respectively, which characterized non-tumorous and tumor tissue (p< or =0.05). One feature which allows differentiation between central tumor and peripheral tumor regions could only be detected in microdissected tissue. Using ProteinChip technology in combination with tissue microdissection it is possible to investigate complex changes at the protein level in hepatocellular cancer associated with tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010826

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology].

Authors:  K Junker; F von Eggeling; J Müller; T Steiner; J Schubert
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

Review 3.  Novel technologies for the discovery and quantitation of biomarkers of toxicity.

Authors:  Fitz B Collings; Vishal S Vaidya
Journal:  Toxicology       Date:  2007-12-05       Impact factor: 4.221

4.  A path or a new road in laboratory diagnostics? Biological mass spectrometry: facts and perspectives.

Authors:  Gábor Elek; Károly Lapis
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

5.  Contribution of laser microdissection-based technology to proteomic analysis in hepatocellular carcinoma developing on cirrhosis.

Authors:  Alexandre Dos Santos; Valérie Thiers; Sokhavuth Sar; Nicolas Derian; Noura Bensalem; Funda Yilmaz; Marie-Pierre Bralet; Béatrice Ducot; Christian Bréchot; France Demaugre
Journal:  Proteomics Clin Appl       Date:  2007-05-11       Impact factor: 3.494

6.  The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Authors:  Amanda F Baker; Tomislav Dragovich; Wendy R Tate; Ramesh K Ramanathan; Denise Roe; Chiu-Hsieh Hsu; D Lynn Kirkpatrick; Garth Powis
Journal:  J Lab Clin Med       Date:  2006-02

7.  Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery.

Authors:  Alain Mangé; Pierre Chaurand; Helene Perrochia; Pascal Roger; Richard M Caprioli; Jérôme Solassol
Journal:  J Proteome Res       Date:  2009-12       Impact factor: 4.466

8.  Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment.

Authors:  C Wibom; F Pettersson; M Sjöström; R Henriksson; M Johansson; A T Bergenheim
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

9.  Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins.

Authors:  Yong-Ning Xin; Ning Geng; Zhong-Hua Lin; Ya-Zhou Cui; Hai-Ping Duan; Mei Zhang; Shi-Ying Xuan
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

Review 10.  Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.

Authors:  Mehdi Mesri
Journal:  Adv Med       Date:  2014-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.